To learn more about our work in #sarcoma research, including topline results from the ozekibart (INBRX 109) trial in #chondrosarcoma, please visit our website at https://t.co/Yht4WhkDqI.

Thank you to everyone who connected with our team at the #MSTS2025 Annual Meeting in Mexico City.

Inhibrx is proud to support the 2025 MSTS Annual Meeting as a Platinum Sponsor. Connect with our team to learn more about our ongoing work in chondrosarcoma with our ozekibart (INBRX-109) program. #MSTS2025 #INBRX109 #BioTechnology

This holiday season, the team at Inhibrx is proud to support the @SDFoodBank once again in its mission to fight hunger and spread hope across San Diego County. We are thankful for the work they do in our local community, providing support to those in need.

Our team was excited to participate in this year's SNO Annual Meeting in Honolulu, where we presented preclinical data evaluating ozekibart (INBRX-109) in glioblastoma models. Learn more about the INBRX-109 program here: https://t.co/Yht4WhkDqI

"This is a significant step forward in treating chondrosarcoma and gives much hope to patients who previously have had no effective systemic therapy," said Dr. Jones. Learn more about the ChonDRAgon study here:

Today at the #CTOS2025 Annual Meeting, Dr. Robin L. Jones presented topline results from ChonDRAgon, the registrational phase 2 study evaluating ozekibart (#INBRX109) in chondrosarcoma, part of the Chondrosarcoma: Sarcoma of the Year session.

TOMORROW AT #CTOS2025 Join us for the oral presentation of results from the ChonDRAgon Phase 2 study evaluating ozekibart (#INBRX109) in #chondrosarcoma. 📍 Presented by Dr. Robin L. Jones ⌛️ 8:30–10:00 AM EST 📑 Session 5: Chondrosarcoma – Sarcoma of the Year

Inhibrx is proud to support the #CTOS2025 Annual Meeting as a Platinum Sponsor. This year’s meeting spotlights #chondrosarcoma as the Sarcoma of the Year, reflecting a shared commitment across the field to advance research in rare sarcomas. #INBRX109

November is #LungCancerAwarenessMonth, a time to raise awareness about lung cancer, the importance of early detection, and the need for novel treatment options. Inhibrx is investigating #INBRX106, our hexavalent OX40 agonist, in NSCLC. Learn more: https://t.co/N2kdoXFZi4

Inhibrx is excited to share the results of ChonDRAgon, our registrational trial of ozekibart (#INBRX109) in chondrosarcoma, as well as updates on colorectal cancer and Ewing sarcoma from our ongoing Phase 1/2 #ClinicalTrial. Read the full press release: https://t.co/PMaomBayR6

Inhibrx is heading to #ESMO25 in Berlin, Germany! Visit us at Booth #2054 to connect with our team and learn more about our clinical research programs in #oncology. #CancerResearch #ClinicalTrials

Learn more about our Phase 1/2 #ClinicalTrial of #INBRX106, actively enrolling patients with advanced NSCLC or head and neck cancer: https://t.co/N2kdoXFZi4 #ClinicalResearch #Biotech #HNSCC

Learn more about the actively enrolling Phase 1 study evaluating ozekibart (#INBRX109): https://t.co/CY9g70r9oB This study is assessing ozekibart, an investigational tetravalent DR5 agonist, in patients with #Ewingsarcoma

Today is #RareCancerDay, a time to shed light on the challenges faced by individuals living with rare and hard-to-diagnose cancers. With limited treatment options, continued research is crucial. Learn more about our #ClinicalTrials: https://t.co/fmCiHx7ZaM

Cancer research is essential to transforming outcomes for patients & families worldwide. On #WorldCancerResearchDay, we highlight our efforts in advancing research & developing potential novel therapies like ozekibart (INBRX-109) & INBRX-106. Learn more: https://t.co/vqqSNHAPHR

Explore our currently enrolling Phase 2/3 HexAgon-HN trial, investigating if #INBRX106 combined with pembrolizumab may be a potential first-line treatment option for patients with recurrent or metastatic #HNSCC expressing PD-L1 (CPS ≥20): https://t.co/P2e8V03Xqv

Inhibrx was honored to take part in the @DukeCancer's #StrikeOutForSarcoma 5K Run/Walk as a gold-level sponsor. Together with patients and advocates, we’re raising awareness for sarcomas like #EwingSarcoma and #Chondrosarcoma.

The 2025 Dragonslayer Walk in Portland was a day of costumes, connection, and community! Inhibrx is proud to support the @nwsarcoma and participate in this year's Dragonslayer Fantasy Dash & Strut in Portland. #chondrosarcoma and #EwingSarcoma.

Inhibrx is evaluating our therapeutic candidate, #INBRX106, in first-line head and neck squamous cell carcinoma (HNSCC) as part of the HexAgon-HN trial. Learn more about the study: